other material
confidence high
sentiment neutral
materiality 0.65
Equillium completes EQ101 Phase 2 enrollment for alopecia areata; advances EQ302 over EQ102
Equillium, Inc.
- Completed enrollment of 36 patients in EQ101 Phase 2 study for alopecia areata; topline data expected Q2 2024.
- Baseline: mean SALT score of 76; 50% severe (SALT 50-94), 33% very severe (SALT >95%).
- 75% of patients had prior treatments; 11 received oral treatments including JAK inhibitors.
- EQ302 oral multi-cytokine inhibitor of IL-15 & IL-21 to be advanced for GI/skin diseases instead of EQ102.